| Ytd | -13.60% | |
| 1y | 52.13% |
| Open | 6.99 | Prev Close | 6.85 | Low | 6.74 | High | 6.99 | Mkt Cap | 248.42M |
| Vol | 64.69K | Avg Vol | 96.67K | EPS | -0.99 | P/E | N/A | Forward P/E | -7.95 |
| Beta | 0.73 | Short Ratio | 7.87 | Inst. Own | 35.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 7.04 | 200-d Avg | 6.90 | 1yr Est | 15.30 |
PROF News
Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst
Telix to partner with companies developing advanced minimally invasive and image-guided ablative tec
Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst con
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strengt
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP f
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.27) per share which missed the analy
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexua
Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raise
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today an
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company&
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company&
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.52) per share which missed the analy
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a comme
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.36) per share which missed the analy
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate can
Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lower
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.20) per share which beat the analyst
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINES
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.38) per share which missed the analy
Profound Medical (NASDAQ:PROF) affirms FY2024 sales outlook from $11.00 million-12.00 million to $11
Current 2024 OutlookAs previously disclosed, based on the Company's current business planning an
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.28) per share which beat the analyst
Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at
Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy a
Stifel analyst Rick Wise maintains Profound Medical (NASDAQ:PROF) with a Hold and lowers the pric
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.420) per share which missed the anal
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earning
Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy a